Recruiting

EmbolizationEmbolization of Middle Meningeal Artery for Subdural Hematoma in Canada (EMMA Can)

Sponsor:

University of Manitoba

Code:

NCT04923984

Conditions

Subdural Hematoma

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Embolization of the middle meningeal artery

Study Details

Brief summary:

EMMA-Can is a prospective cohort study to assess the safety and effectiveness of MMA-embolization for the treatment of CSDH.

Hypothesis- EMMA reduces the recurrence rate of CSDH with or without concomitant surgical evacuation.

Conditions

Subdural Hematoma

Study ID

NCT04923984

Start date

May 1, 2021

Status verified date

Feb, 2026

Completion date

Dec 31, 2029

Anticipated

Primary completion date

Dec 31, 2029

Anticipated

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

\- All patients with subdural hematoma coming to the emergency room or to neurosurgical outpatient clinic.

Exclusion Criteria:

If informed consent cannot be obtained from the patient or their substitute decision maker.
Known allergy to liquid embolic agent

Study Design

Enrollment

1000 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Embolization of Middle Meningeal Artery for Subdural Hematoma

All patients with CSDH will undergo embolization of Middle Meningeal artery

Interventions

Embolization of the middle meningeal artery

embolization of the middle meningeal artery with an embolic agent (Microparticles, liquid embolic agents, SwiftPAC coils or others).

Primary outcome measure

Radiographic recurrence [ Time Frame: up to 90-days for EMMA ]
Symptomatic recurrence [ Time Frame: up to 90-days from EMMA ]

Central Contacts and Locations

Central contacts

Jai Shankar, MD

4313734164 shivajai1@gmail.com

Susan Alcock, RN

2047893669 susan.alcock@umanitoba.ca

Locations

Health Sciences centre

Recruiting

Winnipeg MB, Manitoba, Canada, R3A 1R9

Contacts

Jai Shankar, MD FRCPC

431 373 4164 shivajai1@gmail.com

Susan Alcock

204 789 3996 susan.alcock@umanitoba.ca

Principal Investigator:

Jai Shankar, MD FRCPC

More Information

Sponsor

University of Manitoba

Last update posted

Feb 3, 2026

Last verified

Feb, 2026

Keywords

Embolization
Middle Meningeal Artery
Chronic Subdural Hematoma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Manitoba on 2026-02-03.